From The Editor

1. A Framework For Deploying AI In Clinical Trials Without The Hype 10/15/2026

   Sandboxing, demonstrated value, and a hard line at clinical judgment: a physician-researcher’s three-question test before AI touches a trial.

2. Why Younger Clinical Researchers Are More Wary Of AI Than Their Elders 10/15/2026

   A generational reversal in technology adoption, and why it’s a change-management problem clinical research leaders need to plan for now.

3. Inside The Rush To Accelerated Approval: A Consultant's View 10/13/2026

   A biostatistics consultant on the pattern she keeps seeing: sponsors skipping steps to chase accelerated approval.

4. Why Virtua Health's AI Committee Gives IT The Review, Not The Vote 10/12/2026

   Inside Virtua Health’s AI governance model, where senior operational leaders rank every project, and IT holds no vote.

5. Clinical Trial Tech Fails On Systems, Not Software 10/8/2026

   A Wits RHI sub-investigator explains why fragmented CRFs, labs, and randomization platforms – not bad software – undermine clinical trial technology.

6. Inside A Sponsor-Site Relationship That Actually Worked 10/8/2026

   A former sub-investigator on the co-chair model, escalation process, and CAPA structure that kept one clinical trial site’s sponsor relationship functional.

7. Real-World Data Won't Replace Trials. Here's Its Real Job 10/6/2026

   A biostatistician on where real-world data changes outcomes, and where FDA still won’t accept it as a trial comparator.

8. Inside Virtua Health's Pipeline For Anonymizing Trial Imaging Data 10/5/2026

   How Virtua Health vets, trains, and re-engineers its imaging technology to safely anonymize data for clinical trial research.

    

9. AI Governance Is Becoming A Competitive Edge In Trials 10/1/2026

   Strong data hygiene, formal governance, and human oversight are becoming essential to responsible, scalable AI adoption in clinical trials.

10. Why The Biostatistician's Seat At The Table Keeps Vanishing 9/29/2026

    A Pfizer and Cytel veteran on why statisticians belong at trial design, and why fewer sponsors keep them in-house.